Keywords: Allergan, Botox, Migraine, USA. FDA, Sales potential

Allergan’s shares head higher after US FDA approves Botox to treat chronic migraine

Article | 18 October 2010

Print This

The US Food and Drug Administration on Friday approved Allergan’s (NYSE: AGN) Botox injection (onabotulinumtoxinA), better known as ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in